Barclays’s Ascendis Pharma A/S ASND Stock Holding History

Barclays’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$21.3K	–	5037
2025 Q4	$21.3K	Buy	+100	New	+$20.7K	﹤0.01%	4864
2024 Q2	–	Sell	-119,720	Closed	-$18.1M	–	4858
2024 Q1	$18.1M	Buy	119,720 +97,220	+432%	+$13.9M	0.01%	1039
2023 Q4	$2.83M	Buy	+22,500	New	+$2.24M	﹤0.01%	2623
2019 Q2	–	Sell	-129,500	Closed	-$15.2M	–	6923
2019 Q1	$15.2M	Buy	+129,500	New	+$11.3M	0.01%	998

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's ASND Position: Q1 2026 in Review

Barclays increased its Ascendis Pharma A/S (ASND) stake by 215% in Q1 2026, buying an estimated $5.43M and bringing the position to 35,453 shares worth $8.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1560.

Barclays first reported a position in ASND in Q3 2017 and has held it in 35 quarters since. The position peaked at $13.5M in Q2 2022. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Barclays held 35,453 shares of Ascendis Pharma A/S worth $8.11M as of Q1 2026.
Barclays bought 24,209 Ascendis Pharma A/S shares in Q1 2026, an estimated $5.43M.
Ascendis Pharma A/S made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1560 holding.
Barclays first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 35 quarters since.
Barclays's Ascendis Pharma A/S position peaked at $13.5M in Q2 2022.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.